



when clarity
is critical

COMPANY UPDATE

November 2025

A CMAX SUCCESS STORY!

We're incredibly proud to celebrate another major milestone in early-phase clinical research at CMAX - one that brings real hope to children living with epilepsy.

Our Principal Investigator Sepehr Shakib and the committed CMAX team conducted the first-ever human trial of Relutrigine, a potential new treatment for Developmental and Epileptic Encephalopathy (DEE) - a severe form of epilepsy, often beginning in infancy.

This early-phase study laid the essential foundation for the Phase II trial, which has since shown remarkable results in affected children.

New clinical data revealed that Relutrigine has been well-tolerated in a heavily treated population, with participants experiencing a 75% long-term median seizure reduction and 5 patients becoming seizure-free for more than 28 days.

This incredible achievement, recently announced by Praxis Medicines, offers new hope to children and families impacted by DEE.

At CMAX, we're honoured that our hard work at the beginning of the journey contributed to this outstanding development. It's occasions like these that highlight the value of Phase I clinical research and the pivotal role of committed investigators, volunteers, and clinical teams in advancing the future of medicine.

Congratulations to Professor Shakib and the entire CMAX team for their involvement in this medical innovation!

